FFTY - ETF AI Analysis
Top Page
Innovator IBD 50 ETF (FFTY)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Many of the largest positions have shown strong gains this year, helping support the ETF’s overall performance.
Health Care and Technology Focus
Heavy exposure to health care and technology gives investors access to fast-growing, innovative companies.
Solid Year-To-Date Results
The fund’s year-to-date performance has been positive, indicating that its strategy has recently been working well.
Negative Factors
High Expense Ratio
The ETF charges a relatively high fee, which can eat into long-term returns compared with lower-cost funds.
Concentrated Sector Exposure
A large share of assets in health care and technology means the fund could be hit hard if these sectors weaken.
Limited Geographic Diversification
With almost all holdings in U.S. companies, the ETF offers little exposure to opportunities or diversification outside the United States.
FFTY vs. SPDR S&P 500 ETF (SPY)
AUM73.10M
RegionNorth America
Expense Ratio0.80%
Beta1.35
IssuerCapForce
Inception DateApr 09, 2015
Dividend Yield1.29%
Asset ClassEquity
Index TrackedIBD 50 TR
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume18,379
30 Day Avg. Volume28,021
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
39.77Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering51
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FFTY Summary
Innovator IBD 50 ETF (FFTY) is a U.S. stock fund that follows the IBD 50 Index, a list of 50 fast-growing companies picked for strong sales and earnings. It leans heavily toward health care and technology, and includes well-known names like Advanced Micro Devices (AMD) and Guardant Health. Investors might consider FFTY if they want focused exposure to growth stocks and are looking to add potential high-return companies to their portfolio. However, this ETF can be quite volatile and may go up and down more than the overall market, especially during market downturns.
How much will it cost me?The Innovator IBD 50 ETF (FFTY) has an expense ratio of 0.8%, which means you’ll pay $8 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on selecting top-performing growth stocks rather than passively tracking a broad index.
What would affect this ETF?The Innovator IBD 50 ETF (FFTY), with its focus on growth stocks and heavy exposure to technology and healthcare sectors, could benefit from advancements in innovation, favorable economic conditions, and increased investor interest in high-growth industries. However, it may face challenges from rising interest rates, regulatory changes, or economic slowdowns, which could negatively impact smaller-cap stocks and growth-focused companies. Its U.S.-centric portfolio also makes it sensitive to domestic market trends and policies.
FFTY Top 10 Holdings
FFTY is being steered mainly by a pack of fast-moving U.S. health-care names, with Natera, Hinge Health, Travere, Kiniksa, and Glaukos all rising and giving the fund much of its recent spark. Eton Pharmaceuticals is more of a wild card, with strong growth but choppier trading that can add some bumpiness. Outside of health care, ATI and Ero Copper are quietly contributing steady gains from industrials and materials, while Expedia and WisdomTree provide a smaller boost. Overall, this is a U.S.-centric, growth-heavy ETF leaning hard into innovative health-care stories.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Dave | 3.71% | $2.71M | $4.86B | 95.58% | 80 Outperform | |
| TG Therapeutics | 3.64% | $2.66M | $8.57B | 73.81% | 65 Neutral | |
| Kiniksa Pharmaceuticals | 3.61% | $2.64M | $6.08B | 118.17% | 72 Outperform | |
| WisdomTree | 3.55% | $2.59M | $3.77B | 85.33% | 71 Outperform | |
| Hinge Health, Inc. Class A | 3.54% | $2.59M | $7.45B | 67.73% | 70 Outperform | |
| Travere Therapeutics | 3.50% | $2.56M | $6.15B | 201.66% | 56 Neutral | |
| Aura Minerals | 3.48% | $2.55M | $7.11B | 166.01% | 61 Neutral | |
| Natera | 3.42% | $2.50M | $47.31B | 95.32% | 73 Outperform | |
| Eton Pharmaceuticals | 3.38% | $2.47M | $1.67B | 230.79% | 56 Neutral | |
| Ero Copper | 3.18% | $2.32M | $3.64B | 133.13% | 76 Outperform |
FFTY Technical Analysis
Negative
―
Price Trends
38.15
Negative
39.06
Negative
37.69
Negative
Market Momentum
-0.51
Negative
43.21
Neutral
43.75
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FFTY, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 36.83, equal to the 50-day MA of 38.15, and equal to the 200-day MA of 37.69, indicating a bearish trend. The MACD of -0.51 indicates Negative momentum. The RSI at 43.21 is Neutral, neither overbought nor oversold. The STOCH value of 43.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FFTY.
FFTY Peer Comparison
Comparison Results
Performance Comparison
FFTY
Innovator IBD 50 ETF
36.28
0.78
2.20%
BAMD
Brookstone Dividend Stock ETF
―
―
―
BUZZ
VanEck Social Sentiment ETF
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
PFOE
Pathfinder Focused Opportunities ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents